retatrutide trails FDA Approval Status 2026: Everything We Know So Far retatrutide clinical trials safety Triple

Funding This review received no grant from any funding agency in the public, commercial, or not-for-profit sectors

At Boca Medical Care, we provide comprehensive and personalized solutions for medical weight loss, including the use of Ozempic

For example, in head-to-head trials, patients on the highest dose of Zepbound lost up to 22.5% of their body weight over 72 weeks, while those taking semaglutide GLP-1 (Wegovy) lost about 15% over a similar period

Allergic reactions to Abreva are uncommon but serious

weight loss at target dose (trial data) ~21% (SURMOUNT) CV risk reduction labelled Under study Format Prefilled KwikPen + single-dose autoinjector India price (May 2026) 14,00027,500/month DCGI-approved Yes (March 2025) Generic competition in India No no Indian biosimilar yet Weight-loss percentages are trial averages at target dose individual response varies